BAA for development of drug development tools for adtkd
Active Definitive Contract Awarded Last action
- Contract number
- 75F40124C00106
- Awardee
-
The Critical Path Institute UEI KAEPADMRKHD3
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $2,774,844
Award facts
- Contract value 82% obligated
-
- $2,774,844.00 Current, with exercised options
- $3,375,844.00 Potential, with all options
- Completion date 56% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Tucson, AZ 85718, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $923,844 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $900,000 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $951,000 |
About this award
The Food and Drug Administration awarded a $3.375 million definitive contract to The Critical Path Institute for development of drug development tools for autosomal dominant tubulointerstitial kidney disease (ADTKD) on August 16, 2024, with a ceiling value of $3.375 million and ultimate completion date of August 21, 2028.
The originating solicitation addresses development of clinical phenotyping frameworks, biomarker landscape analysis, and patient identification tools to support FDA regulatory science and drug development for ADTKD. Performance is in Tucson, Arizona. The contract is priced on a firm fixed price basis.
Place of performance is Tucson, AZ. Wake Forest University Health Sciences subcontracts on biobanking and prospective longitudinal biomarker analysis including fluid and imaging markers, with specific focus on ADTKD patient identification, sample collection, processing, and biomarker measurement delivery to the prime. C-Path performs clinical data ingestion, phenotypic mapping, curation, and landscape assessment of biochemical and imaging tools relevant to ADTKD.
Service Contract Inventory data shows FY2025 invoicing of $981 thousand across 4.6 FTEs and 9,526 contractor hours, with 54 percent of hours subcontracted. The derived government-paid rate in FY2025 was $102.97 per hour. FY2024 invoicing totaled $26 thousand across 0.1 FTEs and 240 contractor hours at $107.93 per hour. A no-cost modification in August 2024 clarified the deliverables schedule and incorporated FAR 52.222-90 and Executive Order 14398.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| Wake Forest University Health Sciences | $427,661 | |
| Wake Forest University Health Sciences | $323,189 | |
| Wake Forest University Health Sciences | $441,890 |
Quick answers
Who was awarded contract 75F40124C00106?
75F40124C00106 was awarded to The Critical Path Institute by Food and Drug Administration (Department of Health and Human Services) on August 16, 2024.
How much is contract 75F40124C00106 worth?
The government has obligated $2,774,844 on 75F40124C00106. Its potential value, with all options, is $3,375,844.
Was contract 75F40124C00106 competed?
The extent of competition for 75F40124C00106 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award